CRT is an essential treatment for patients with heart failure and reduced ejection fraction as it can restore left ventricular (LV) electrical and mechanical synchrony. It has been shown to increase quality of life, improve functional status, reduce hospitalisation, improve LV systolic function and reduce mortality in properly selected patients.
QRS Duration and Morphology
Since CRT targets electrical dyssynchrony, QRS duration and morphology have been used to determine which patients will receive maximum benefit from CRT. Based on subgroup analysis of large CRT trials, current guidelines consider CRT implants to be a Class I indication in patients with left bundle branch block (LBBB) and QRS >150 msec, with softer recommendations for QRS <150 msec and non-LBBB patients. 3 An analysis of data from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) trial demonstrated that only patients with LBBB had a reduction in heart failure events and that non-LBBB patients may have been harmed by CRT. 4 Similar data were published from the Resynchronization/ Defibrillation for Ambulatory heart Failure Trial (RAFT). 5 No benefits were found to result from CRT in right bundle branch block (RBBB) patients in five randomised controlled clinical trials or in a subset of 1,233 patients with non-LBBB QRS morphology from four randomised trials. 6, 7 However, data on QRS morphology are mixed and no large CRT trial has used QRS morphology as an enrolment criterion. There is no standardised definition of LBBB, especially with respect to predicting electrical dyssynchrony and response to CRT. In addition, some patients with RBBB and intraventricular conduction delay may have a LBBB-like activation pattern of the left ventricle and could respond to CRT. 8 To this end, the MADIT-CRT trial showed that, in patients with non-LBBB morphologies and PR intervals >230 msec, there was a 67% reduction in risk of the combined primary endpoint of heart failure and death and a 76% reduction in the risk of death in the CRT device (CRT-D) arm versus the ICD-only arm. 9 Data from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) trial also showed benefit in patients with RBBB receiving CRT. 10 QRS duration is a good predictor of CRT response. QRS duration is a criterion for every large clinical trial showing benefit in CRT. Trials randomising patients with narrow QRS (<120 msec or 130 msec)
show no benefit or potential harm for patients receiving CRT, even in the presence of mechanical dyssynchrony. 11 An analysis of four trials by Cleland et al. showed that QRS duration was the best predicator of benefit from CRT placement, irrespective of QRS morphology, with response seen once QRS duration was >130 msec. 12 Subgroup analyses have shown that the greatest CRT benefit is derived in the cohort of patients with a QRS duration of 150 msec, as reflected in the guidelines for CRT placement. 3, 10, 12 Since correcting dyssynchrony is the core benefit of CRT, imaging has been added to 12-lead ECG to expand and refine the population of patients that might benefit from this therapy. The presence of mechanical dyssynchrony on echocardiography or MRI has been shown to predict which patients perform best after CRT placement.
prospectively studied echocardiographic measures of dyssynchrony, found they had only modest sensitivity and specificity to predict CRT response with significant variability in the measurement of dyssychrony studied. 15 It was conjectured that this was due to the complexity of the dyssynchrony parameters and significant interobserver variability. Newer measures of mechanical dyssynchrony, as assessed by echocardiography and MRI, have shown promise. 13, 14 Apical rocking and septal flash are simple visual echocardiographic parameters of a LBBB-like contraction pattern that is characterised by late contraction of the lateral left ventricle. Apical rocking specifically refers to a short septal motion of the apex due to early contraction of the septum and late contraction of the lateral wall. 13 Septal flash is defined by early contraction of the septum causing a short rapid inward motion of the septum. 13 The has also shown the ability to predict echocardiographic response to CRT better than QRS duration or morphology.
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Lead Placement
Another strategy for improving CRT outcome is optimisation of lead placement. Since the lateral left ventricle is the latest-activating area in LBBB, the lateral or posterolateral left ventricle -in general -is the preferred target for LV lead placement, but the optimal place for such placement may vary for a given patient. Early data showed that the placement of anterolateral or posterolateral leads was superior to anterior lead placement. 20 However, analysis of the
Comparison of Medical Therapy, Pacing and Defibrillation in Heart
Failure (COMPANION) trial showed that no particular lead location was associated with an improved response. 21 Other studies show that apical LV lead placement is associated with worse outcomes than non-apical leads. 22 The Targeted responses. 26, 27 Even patients with a lead placed in the LV apex had a good response to CRT if the lead showed late LV activation. 28 Leads placed in an electrically late-activating segment predicted by ECGI or vectorcardiography have also been shown to enhance acute response to CRT. [28] [29] [30] However, preliminary results from the CRT Implant Strategy
Using the Longest Electrical Delay for Non-left Bundle Branch Block
Patients (ENHANCE-CRT) pilot study, which randomised 248 patients to LV lead placement guided by QLV versus standard LV lead placement in non-LBBB subjects, showed no statistical difference. 31 Applicability of CRT therapy can also be limited by the anatomic constraints of the coronary sinus (CS). In 5-10% of patients, LV lead placement is unsuccessful due to either CS inaccessibility, high LV pacing thresholds, or phrenic nerve stimulation. 1, 2, 6 In addition, >50% of patients have only one CS branch that is suitable for lead placement, making it difficult to target LV lead placement to areas of late activation or dyssynchrony in all subjects.
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New Catheter Approaches to LV Synchronisation
Endocardial LV pacing offers many potential benefits over epicardial LV pacing. LV endocardial leads can be targeted to any area of the left ventricle due to the lack of anatomic constraints from the CS.
In addition, LV endocardial pacing thresholds are lower than epicardial leads and phrenic nerve stimulation can be more readily avoided.
Animal and human studies have shown that the LV endocardium provides a favourable acute haemodynamic response to LV
Drugs and Devices
pacing. This is likely to due to more rapid LV endocardial impulse conduction leading to shorter LV activation times as compared with epicardial pacing. were CRT non-responders or who had failed implants. The clinical response rate was 59%. However, despite anticoagulation there was a high rate of thromboembolic complications (stroke rate was 2.6 per 100 patient years and there were 14 transient ischaemic attacks in nine patients), but no cases of lead-related mitral regurgitation were seen. 34 Another technique for LV endocardial pacing involves passing the lead through the intraventricular septum and into the lateral LV myocardium. In a preliminary study, all patients were successfully implanted with this technique and eight out of nine were considered responders. All patients were on anticoagulation and no cerebrovascular accidents or transient ischaemic attacks were reported during a mean follow-up of 8.7 months. 35 The larger Pilot Study of Interventricular Septal Puncture for Cardiac
Resynchronization Therapy to Treat Heart Failure (LV-CONSEPT) trial (NCT01818765), designed to evaluate outcomes for this approach to LV lead placement, has completed enrolment.
Preliminary data from LV endocardial pacing via the LV septum has also been shown to improve haemodynamics versus right ventricular pacing and to have similar haemodynamic response to lateral LV endocardial biventricular pacing. This technique utilises a specialised pacing lead with a fixed 4 mm helix. The helix has a thin coating on the proximal portion, with only the distal 1.27 mm electrode exposed.
The lead is screwed into the intraventricular septum until LV septal capture is confirmed. The advantage of this technique is that the lack of hardware in the left ventricle eliminates the need for anticoagulation. 36 The final option for LV endocardial pacing is leadless pacing. The 50 The clinical response rate was 70% and mean ejection fraction increased from 30% to 44%. There was also a significant improvement in NYHA class, with participants' symptoms improving by one NYHA class on average. Another recent series of 39 patients with RBBB from the same group showed that His bundle pacing was successful in 95% of patients and there was a favourable clinical response in 76% of patients. 50 His bundle pacing offers many potential advantages:
• Faster impulse propagation due to endocardial and His-Purkinje system recruitment; 46, 47 • Direct access to the anatomic area of interest; 46 • Lack of need for optimisation of CRT lead placement or ventriculoventricular (VV) timing, since recruitment of the distal His-Purkinje system and fascicles should result in normalisation of LV electrical activation; 49, 50 • Endocardial pacing with QRS narrowing should avoid the negative CRT response that is sometimes associated with LV epicardial pacing due to ventricular proarrhythmia or unchanged dyssynchrony pattern. 51 While His bundle pacing offers promise as a first-line therapy, current drawbacks include:
• lack of randomised trials showing clinical improvement or mortality benefit;
• high lead revision rates;
• higher thresholds and current battery drain associated than for CRT; and
• lack of significant long-term data of lead performance in the His position.
The 
Narrow QRS
Narrow QRS patients are generally excluded from CRT due to the lack of benefit demonstrated in multiple large randomised controlled trials.
However, selected patients with narrow QRS do benefit from CRT. Many studies have shown the CRT pacing coupled with atrioventricular (AV) node ablation, either with a LV lead or His bundle pacing, have reported improved heart failure symptoms and LV ejection fraction in patients with AF, LV dysfunction and congestive heart failure. 52, 53 The recently published Abate and Place in AF plus CRT (APAF-CRT) trial randomised 109 patients with a narrow QRS and permanent AF to AV node ablation and CRT versus rate control. The CRT-AV node ablation group had a significant reduction in death from any cause or hospitalisation for heart failure (12% versus 33%) and a trend towards decreased mortality (4% versus 12%). 54 While CRT for narrow QRS patients in sinus rhythm is currently contraindicated, some studies have suggested that in selected patients the majority of acute haemodynamic improvement from CRT is due to AV optimisation, thus improving LV preload rather than correcting dyssynchrony. 55 The His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) trial (NCT02671903) will randomise 160 patients with a LV ejection fraction <40% with narrow QRS or RBBB and PR interval >200 msec to His bundle pacing with AV optimisation versus standard congestive heart failure therapy, testing the hypothesis that AV optimisation improves outcome in this group of patients. with SonR versus echocardiographic optimisation. 59 There was a 75%
response rate in the SonR group versus 70% in the control group, with a 35% relative reduction in the risk of hospitalisation for heart failure.
The SyncAV ™ algorithm (Abbott) regularly calculates the PR interval from device electrograms and automatically adjusts the AV delay to allow for intrinsic septal activation before biventricular pacing. This algorithm shortens QRS duration during biventricular pacing to a greater extent than statically optimised AV and VV delays and LV-only pacing. 60 A recent randomised study showed that programming AV delays and VV timing to promote fusion with intrinsic septal activation and targeting the shortest QRS duration with CRT pacing resulted in a higher rate of reverse remodelling than nominal Using a lead-based micro-accelerometer to detect mechanical vibrations (endocardial acceleration signal), AV and VV delays are dynamically optimised weekly during rest and exercise to maximise the peak endocardial acceleration signal, which is a surrogate for LV contractility CRT AutoAdapt ™ (Biotronic) AV and VV optimisation IEGM-based method similar to AdaptiveCRT. AV interval to RV and LV is measured based on sensed and paced atrial beats. LV-only pacing is delivered if A-paced AV interval is <250 msec and A to LV interval is longer than A to RV interval, otherwise biventricular pacing is delivered. AV delay is dynamically set at 70% of AV interval or AV interval -40 msec, depending on which is shorter
A 75-year old male CRT non-responder with an ejection fraction of 30%, left bundle branch block with QRS duration of 160 msec, and New York Heart Association Class III heart failure symptoms due to cardiac amyloidosis. (A) RV-LV=0 msec. Bull's eye plot and endocardial GLS graph demonstrate impaired GLS (−10.53%) in an apical sparing pattern typical of cardiac amyloidosis. Segmental peak systolic strain curves illustrate a wide range in the timing of peak systolic strain, with early systolic shortening of the septum (red arrows) and late peak contraction of the lateral wall (blue arrow). (B) LV only. Note the similarly impaired GLS (−11.68%), though with time to peak strain occurring over a narrower range. (C) RV-LV=40 msec. Peak systolic deformation is markedly improved, particularly in the septal and inferior walls, with a significant increment in GLS (−15.11%). Note the narrow range of peak strain values. (D) Velocity vector tracking demonstrates severe septal-lateral wall dyssynchrony and severely impaired longitudinal strain with RV-LV=0 msec. (E) Some improvement with LV-only pacing. (F) Near
Other Methods
Invasive haemodynamic AV and VV optimisation
An open-lumen micromanometer catheter or pressure wire directly placed in the LV is used to target maximum rate of increase of LV pressure (dP/dt max ) to optimise AV and VV timing Impedance cardiography (Task Force® Monitor Systems, CNSystems) AV and VV optimisation
Multiple electrodes placed on the chest, neck, and abdomen measure transthoracic impedance. Increased aortic blood flow and cardiac output are associated with lower transthoracic impedance. AV and VV timings are optimised to target the lowest impedance value, which corresponds to maximum cardiac output Acoustic cardiography (Audicor ™ , Inovise Medical) AV and VV optimisation
Using an ECG electrodes in V3 and V4 positions to detect the first, second and third heart sounds and the QRS, time from onset of the Q wave to the mitral component of S1 is measured (electromechanical activation time) and the strength of S3 is assessed. AV and VV timings are optimised for the shortest electromechanical activation time and strongest S3
Finger plethysmography AV and VV optimisation AV and VV delays are optimised using finger oximetry to target the maximum pulse amplitude of the finger plethysmogram wave form Noninvasive blood pressure measurement AV and VV optimisation AV and VV delays optimised with serial blood pressure measurements targeting the peak mean systolic blood pressure over multiple measurements Drugs and Devices settings (74% versus 53%). 61 
CRT with an ICD
There has been significant debate as to whether the addition of ICD therapy to CRT improves outcomes. The majority of patients who meet the CRT criteria are also suitable for an ICD for the primary prevention of sudden cardiac death. Furthermore, most patients enrolled in the pivotal trials demonstrating CRT benefit also received an ICD. 62 Multiple retrospective studies have shown better survival in patients who received a CRT-D rather than a CRT pacemaker (CRT-P). 63, 64 Additionally, in patients with ischaemic cardiomyopathy, CRT-D implantation was associated with improved mortality over CRT-P. 63, 64 This may be because the patients who received CRT-P were generally older, more likely female and more often had non-ischaemic cardiomyopathy as well as a greater number of comorbidities, which likely contributed to their lower survival. 63, 64 In its favour, CRT-P is costs less and has been associated with fewer complications than CRT-D. 65 It should be noted that large cohort studies have shown that in patients with non-ischaemic cardiomyopathy, the addition of ICD therapy to CRT is not associated with improved outcomes; 66 however, in non-ischaemic cardiomyopathy with scarring, specifically LV mid-wall fibrosis seen with cardiac MRI, CRT-D improves mortality and reduces major adverse cardiac events. 67 The Prospective Observational Study of the ICD in Sudden Cardiac
Death Prevention (PROSe-ICD) study developed a clinical decision tool using biomarkers and clinical variables to help guide those who would benefit from ICD therapy in addition to CRT. 68 The CeRtiTuDe study showed that while patients receiving CRT-P had a higher mortality, 95% of this excess mortality was not due to sudden cardiac death. 69 The guidelines currently recommend CRT-P for NYHA Class IV heart failure and favour CRT-D for younger patients with milder heart failure, with ischaemic heart disease and life expectancy >1 year. 65 CRT-P is recommended for older patients with more advanced congestive heart failure, severe renal dysfunction, frailty and lower life expectancy.
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Conclusion
CRT is a potent therapy for improving outcomes and reducing mortality in heart failure. Despite being an established first-line therapy, significant issues remain in patient selection and the proper delivery of CRT. On-going research into new tools and methods to improve CRT therapy will allow for further improvements in outcomes in what has already proven an innovative therapy for the treatment of symptomatic LV systolic dysfunction.
